Melanotan-I – Research Compound Profile

Melanotan-I – Research Compound Profile

Category: Dermatological Research | Molecular Type: Synthetic Linear Tridecapeptide (α-MSH Analog) | Research Status: A related pharmaceutical formulation is FDA-approved for a specific dermatological indication (2019); the research-grade form sold here is not FDA-approved for human use

This page compiles published research data for qualified researchers. Melanotan-I is sold exclusively as a research compound, is not approved for human use, and this page does not constitute medical advice.

Purchase for Research →

Molecular Overview

Melanotan-I (MT-1, afamelanotide, [Nle⁴-D-Phe⁷]-α-MSH) is a synthetic 13-amino acid linear peptide analog of endogenous alpha-melanocyte stimulating hormone (α-MSH). It was first synthesized at the University of Arizona in 1980 by Sawyer, Hruby, and colleagues [1]. The key structural modifications — substitution of norleucine at position 4 and D-phenylalanine at position 7 — confer resistance to enzymatic degradation by serum proteases and peptidases, extending biological activity by several orders of magnitude compared to native α-MSH [1][3].

Unlike the cyclic analog Melanotan-II, MT-1 is linear and carries a free (non-amidated, non-cyclized) C-terminus, which is the principal structural distinction between the two peptides and likely contributes to their differing receptor-subtype selectivity profiles. MT-1 selectively activates the melanocortin 1 receptor (MC1R) on melanocytes, stimulating eumelanin biosynthesis and conferring UV-independent photoprotection [1][2]. In vitro studies demonstrated that MT-1 stimulates tyrosinase activity up to 1,000-fold more potently than native α-MSH [3][16]. Unlike the cyclic analog Melanotan-II, MT-1 does not significantly activate MC3R, MC4R, or MC5R at the concentrations evaluated in published studies, resulting in a more selective pharmacological profile [1][14].

The pharmaceutical-grade formulation of afamelanotide (marketed as Scenesse®) received regulatory approval from the European Medicines Agency in 2014 and the U.S. FDA in 2019 for a specific dermatological indication, making it the first synthetic α-MSH analog to achieve regulatory approval [4]. Further regulatory detail is noted in the Regulatory Status section below.

Mechanism of Action

Melanotan-I exerts its biological effects through selective agonism of the melanocortin 1 receptor (MC1R), a G-protein coupled receptor expressed on the surface of epidermal melanocytes, keratinocytes, fibroblasts, and endothelial cells [1][2]. When MT-1 binds MC1R, it triggers the adenylyl cyclase–cAMP–protein kinase A (PKA) signaling cascade, which activates the transcription factor CREB and upregulates microphthalmia-associated transcription factor (MITF). MITF in turn drives expression of tyrosinase and tyrosinase-related proteins (TRP-1, TRP-2), the key enzymes responsible for converting L-tyrosine and L-DOPA into eumelanin — the brown-black pigment that absorbs ultraviolet and visible light across a broad spectrum [2][3].

Critically, MT-1 induces eumelanin synthesis independently of UV radiation — a mechanistic distinction from natural tanning, which requires UV-induced DNA damage (pyrimidine dimers) to trigger the p53 → POMC → α-MSH → MC1R signaling axis [2][12]. This UV-independent melanogenic pathway has been central to the investigation of MT-1 as a photoprotective agent.

Beyond melanogenesis, MC1R activation by MT-1 has been shown to initiate additional photoprotective pathways. Afamelanotide was observed to enhance nucleotide excision repair (NER) of UV-induced cyclobutane pyrimidine dimers (CPDs) in keratinocytes, accelerating DNA damage repair even in the absence of new UV exposure [17]. MT-1 also upregulates antioxidant defenses — including superoxide dismutase activity and free radical scavenging — and exerts anti-inflammatory effects through MC1R-mediated stimulation of interleukin-10 (IL-10) secretion and suppression of pro-inflammatory cytokines such as IL-8 [2][16]. Pharmacokinetic analysis published by Minder et al. (2017) characterized the compound’s absorption and distribution profiles across different delivery formats studied in the literature [11].

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published literature and pharmaceutical stability data indicate the following characteristics for Melanotan-I:

• Lyophilized form: Stable at −20 °C (−4 °F) for extended periods (up to 24 months based on manufacturer stability data). Shorter-term storage at 2–8 °C has been reported for durations of up to 6 months [11].
• Reconstituted solution: Studies have utilized refrigerated storage at 2–8 °C (35.6–46.4 °F) with solutions typically used within 4 weeks of preparation [11].
• Photosensitivity: Melanocortin peptides are photosensitive and may degrade with prolonged UV or light exposure — a point of particular note for a molecule under investigation as a photoprotective agent. Published protocols specify light-protected storage conditions [4][15].
• Freeze-thaw sensitivity: Freeze-thaw cycles can promote peptide aggregation and degradation. Published pharmaceutical development data indicate that reconstituted solutions should not be frozen [11].
• Linear-peptide handling considerations: Because MT-1 lacks the cyclic lactam constraint present in Melanotan-II, its linear backbone is comparatively more exposed to proteolytic and hydrolytic attack in solution, which is consistent with the shorter documented solution-stability window relative to the cyclic analog.
• Approved delivery format: The approved pharmaceutical form utilizes a controlled-release bioresorbable implant intended for periodic administration by a healthcare provider; pharmacokinetic data for this delivery format were published by Minder et al. (2017) [11]. This is distinct from the lyophilized research-grade material.

Analytical Characterization

Research-grade Melanotan-I is characterized with an orthogonal analytical panel. Reverse-phase HPLC provides the primary purity measurement, resolving deamidated and oxidized variants from the intact linear tridecapeptide. Electrospray or MALDI mass spectrometry confirms the intact monoisotopic mass; because MT-1 is not cyclized, its expected mass differs from Melanotan-II by the mass of one water molecule plus the mass difference between a free C-terminal carboxylic acid and an amidated ring-closed terminus, providing a straightforward mass-based means of distinguishing the two related peptides in a mixed or misidentified sample. A peptide-content assay accounts for residual counter-ion, water, and buffer salts relative to gross vial mass. Researchers should retain the quality assurance documentation for each lot.

Key Published Research Findings

• Photoprotection in EPP (Phase III): In the landmark 2015 New England Journal of Medicine Phase III randomized controlled trial (n=168), Langendonk et al. reported that patients receiving afamelanotide implants experienced a statistically significantly longer median duration of pain-free sun exposure than the placebo group over six months, with fewer phototoxic reactions and faster recovery times [9].

• Eumelanin induction in human subjects: In a 2000 Photochemistry and Photobiology study, Dorr et al. documented a statistically significant increase in epidermal melanin density (measured by reflectance spectrophotometry) in fair-skinned human volunteers over a 10-day study period. Histological examination revealed a substantial reduction in sunburn cells compared to untreated controls [8].

• Synergistic melanogenesis with UV exposure: In a 2004 Archives of Dermatology study, Dorr et al. observed that the combination of MT-1 and controlled solar UV radiation produced significantly greater melanin density increases than either stimulus alone in human volunteers [5].

• Vitiligo repigmentation: In a 2015 JAMA Dermatology randomized multicenter trial (n=28), Lim et al. found that afamelanotide combined with narrowband UVB phototherapy achieved statistically significantly greater repigmentation than phototherapy alone, with particularly strong results observed on the face and upper extremities [18].

• DNA repair enhancement: Preliminary results from the CUV156 study (CLINUVEL, 2023) indicated that afamelanotide enhanced repair of UV-induced DNA damage in skin biopsies of a small cohort of research subjects with a rare DNA-repair disorder, suggesting direct genomoprotective activity via MC1R signaling [17].

• Long-term efficacy and tolerability: A three-year observational study by Barman-Aksözen et al. (2020) in Orphanet Journal of Rare Diseases involving 115 EPP patients demonstrated sustained increases in phototoxic burn tolerance time with repeated afamelanotide administrations, accompanied by significant quality-of-life improvements and no serious drug-related adverse events [7][10].

• Anti-inflammatory and antioxidant activity: As reviewed by Brzoska et al. (2008) in Endocrine Reviews and Kim & Garnock-Jones (2016) in American Journal of Clinical Dermatology, MC1R activation by MT-1 reduces oxidative stress through enhanced superoxide dismutase availability and free radical scavenging. In vitro evidence demonstrated IL-8 suppression in sebocytes, providing a mechanistic basis for further inflammatory-pathway research [2][15][16].

• MC1R selectivity: As reported by Dorr et al. (1996) in Life Sciences, MT-1 does not significantly activate MC3R, MC4R, or MC5R at the concentrations studied, distinguishing it pharmacologically from the non-selective cyclic analog Melanotan-II [1][14].

Safety Profile in Published Literature

Published clinical studies have documented the following safety observations for Melanotan-I/afamelanotide:

• Nausea: The most frequently reported adverse effect across the studies reviewed, affecting a substantial proportion of subjects in Phase I trials. Described as mild and self-limiting, typically resolving within 30–60 minutes. Frequency was observed to diminish with repeated administrations [5][9].

• Facial and upper-body flushing: Observed in a meaningful minority of subjects in Phase I studies, usually within minutes of administration. Attributed to MC1R activation on vascular endothelial cells. Typically subsided within 1–2 hours [5][8].

• Headache: Reported in a notable proportion of subjects in Phase III EPP trials. Generally described as mild and transient [9][10].

• Skin darkening (primary pharmacodynamic effect): Progressive hyperpigmentation is the expected pharmacological outcome. Freckle darkening and new lentigines were observed, particularly in fair-skinned subjects. These effects were reported to be reversible upon discontinuation over 4–8 weeks as melanin turned over with the epidermis [5][15].

• Fatigue and lethargy: Reported in a smaller proportion of subjects in Phase III trials. Generally described as mild and self-resolving [9].

• Toxicology: The three-year observational study by Barman-Aksözen et al. (2020) involving 115 EPP patients reported no serious drug-related adverse events with repeated implant administrations over the study period [7][10].

• Rare reports: One case report in the literature documented acute priapism following melanotan injection, though this adverse event has been more commonly associated with the non-selective Melanotan-II [14].

Interpretive Limits

Several of the human efficacy findings above derive from studies with small or narrowly defined cohorts, and the strongest controlled-trial evidence (the Phase III EPP data) applies to a specific patient population studied under a specific dosing regimen not replicated in the research literature on lyophilized MT-1. Extrapolating the magnitude of any reported effect to a different formulation, exposure pattern, or population is not supported by the cited data.

Regulatory Status

• FDA approval: A related pharmaceutical formulation (afamelanotide, marketed as Scenesse®, CLINUVEL Pharmaceuticals) was approved by the FDA in October 2019 and by the European Medicines Agency (EMA) in 2014 for a specific dermatological indication; this regulatory history is noted here for completeness only and does not apply to the research compound described on this page [4].

• Approved formulation: The approved product is a controlled-release bioresorbable implant administered periodically by a healthcare provider. This is distinct from the lyophilized research-grade compound sold here [4][11].

• Clinical trial status: Additional clinical investigations are ongoing, including studies related to DNA-repair disorders, vitiligo, polymorphous light eruption, and other photodermatoses. Active trials are listed on ClinicalTrials.gov [4][17].

• Research compound notice: The lyophilized form of Melanotan-I sold by peptide suppliers is not the FDA-approved pharmaceutical product (Scenesse®) and is sold exclusively for research purposes. It has not been approved by the FDA for human consumption.

• Regulatory review: Polańska, Wegner et al. (2024) published a comprehensive review in Postepy Dermatologii i Alergologii covering the regulatory landscape and research applications of afamelanotide across dermatological contexts [4].

References

1. Proc Natl Acad Sci USA (1980) — Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. View Source

2. Endocrine Reviews (2008) — Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. View Source

3. J Invest Dermatol (2006) — Barnetson RSC, Ooi TKT, Zhuang L, et al. [Nle4-D-Phe7]-α-MSH significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. View Source

4. Postepy Dermatol Alergol (2024) — Polańska A, Wegner J, et al. Afamelanotide in protoporphyria and other skin diseases: a review. View Source

5. Arch Dermatol (2004) — Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. View Source

7. Orphanet J Rare Dis (2020) — Barman-Aksözen J, Nydegger M, et al. Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide — a three-year observational study. View Source

8. Photochem Photobiol (2000) — Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin in humans. View Source

9. N Engl J Med (2015) — Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. View Source

10. Br J Dermatol (2015) — Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. View Source

11. Clin Pharmacokinet (2017) — Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. View Source

12. JAMA (1991) — Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. View Source

14. Life Sci (1996) — Dorr RT, Lines R, Levine N, et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot Phase I clinical study. View Source

15. Expert Rev Clin Pharmacol (2021) — Wensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. View Source

16. Am J Clin Dermatol (2016) — Kim ES, Garnock-Jones KP. Afamelanotide: a review in erythropoietic protoporphyria. View Source

17. CLINUVEL (2023) — CUV156 Study First Results: DNA repair in xeroderma pigmentosum patients treated with afamelanotide. View Source

18. JAMA Dermatol (2015) — Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Melanotan-I, as sold by Iron Peak Peptides, is supplied exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. A related pharmaceutical formulation (afamelanotide/Scenesse®) is separately FDA-approved for a specific dermatological indication administered under physician supervision; that regulatory status does not apply to the research material described here. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase Melanotan-I for Research →